The average 12-month price objective among brokers that have issued a report on the stock in the last year is $86.00. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Cetera Investment Advisers now owns 7,681 shares of the company’s stock worth $250,000 after acquiring an additional 932 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock. Vaxcyte Company Profile(Get Free Report)Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases.